Europass Curriculum Vitae Personal information
Surname(s) / First name(s) Ferrucci Andrea
Address(es) via Apollo Pizio, num. 3 – 00135 Rome
Occupational field Cardiologist Work experience
Occupation or position held MD, specialist in cardiology
Main activities and responsibilities Clinical Management of High-Risk patients, Hypertension Unit, Division of Cardiology,
Name and address of employer Division of Cardiology, Faculty of Medicine, University of Rome Sapienza, Sant’Andrea Hospital,
Type of business or sector Cardiovascular Medicine
Occupation or position held MD, specialist in cardiology
Main activities and responsibilities Clinical Management of High-Risk patients, Hypertension Unit, Intensive Coronary Care Unit,
Name and address of employer Cardiology Unit, Division of Internal Medicine, Institute of “Malattie Tropicali”, Policlinico Umberto I of
Type of business or sector Cardiovascular Medicine
Education and training
Title of qualification awarded Specialist in Cardiologist
Occupational skills covered Training Cardiologist
providing education and training School of Cardiology, Division of Cardiology, Faculty of Medicine, University of Catania, Catania, Italy.
Occupational skills covered Resident Physician
For more information on Europass go to ht p:/ europass.cedefop.europa.eu
Name and type of organisation Cardiology Unit, Division of Internal Medicine, Institute of “Malattie Tropicali”, Policlinico Umberto I of
providing education and training Rome, Rome, Italy.
Title of qualification awarded Medical Doctor
Occupational skills covered School of Medicine
providing education and training Faculty of Medicine, University of Rome Sapienza, Policlinico Umberto I, Rome, Italy.
Personal skills and competences
Mother tongue(s) Italian
Other language(s) English Understanding Speaking English C1 Society Memberships, Awards and Honors
Name of the Society Italian Society of Hypertension (SIIA) membership
Name of the Society Italian Society of Cardiovascular Prevention (SIPREC) membership
Experience as Clinical Trial Investigator
Title of the Trial Prevalence of Abdominal Obesity and Metabolic Syndrome and Their Association with Organ Damage
in Hypertension and Lipid Clinics (PROMISE)
Occupational skills covered Sub-Investigator
Title of the Trial International Survey Evaluating Microalbuminuria Routinely by Cardiologists in Patients with
Occupational skills covered Sub-Investigator
Dates 2008 (ongoing)
Genetics and Genomics of Hypertension Associated with microinflammation, oxidative stress, Chronic
Title of the Trial Renal Disease and heart failure (InGenious HyperCare): genetics, genomics and proteomics of
transition from hypertension to heart failure”
Occupational skills covered Sub-Investigator
Dates 2008 (ongoing)
For more information on Europass go to ht p:/ europass.cedefop.europa.eu
A randomized, double-blind, placebo-controlled, parallel-group study to determine wheter, in patients
with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conventional
Title of the Trial treatment, reduces cardiovascular and renal morbidity and mortality. ALiskiren Trial In Type 2 diabetes
Using cardiorenal Disease Endpoints (ALTITUDE) (CSPP100E2337)” (code EUDRACT 2007-000860-
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy
and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with
Title of the Trial aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg
monotherapy (CSPP100A2332)” (code EUDRACT 2005-004579-39)
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia
Title of the Trial (ETERNAL) (code EUDRACT 2006-001715-30)
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
An 8-week double-blind, randomized, active-control, parallel-grupp study to evaluate the efficacy and
Title of the Trial safety of the combination of aliskiren / amlodipine / HCTZ to patients with moderate to severe
hypertension (CSPA100E2302)” (code EUDRACT 2008-003199-23)
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group
study to evaluate the efficacy and safety of aliskiren administered alone and in combination with
Title of the Trial amoldipine in patients with essential hypertension (CSPA100A2305)” (code EUDRACT 2008-001609-
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group
Title of the Trial study to evaluate the efficacy and safety of aliskiren administered alone and in combination with
amoldipine in patients with essential hypertension (CSPA100A2305)” (code EUDRACT 2008-001609-
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
Efficacy and safety of zofenopril plus hydrochlorothiazide combination versus irbesartan plus
Title of the Trial hydrochlorothiazide combination in metabolic syndrome patients with essential hypertension not
controlled by previously monotheraphy (MEN/09/ZOF-IPE/001)” (code EUDRACT 2009-012993-10)
Occupational skills covered Sub-Investigator
For more information on Europass go to ht p:/ europass.cedefop.europa.eu
Dates 2010 (ongoing)
A multicentre, multinational, randomised, double-blind, pilot, ascending dose for non responder,
parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5
Title of the Trial mg vs. Irbersartan 150 mg plus HCTZ 12.5 mg in elderly subjects (age > 65 years) affected by
Isolated Systolic Hypertension never treated or non responder to previous antihypertensive therapy
(monotherapy or association of maximum two treatments) (LUMI/10/ZOF-HYP/001)” (code EUDRACT
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
Dates 2011 (ongoing)
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly
Title of the Trial People. Aliskiren Prevention Of Later Life Outcomes (APOLLO) (CSPP100G2301) (code EUDRACT
Type of the Trial Phase III Interventional Clinical Trial
Occupational skills covered Sub-Investigator
For more information on Europass go to ht p:/ europass.cedefop.europa.eu
IMMEDIATE Contact: Moira Bishop New Medication Translations for World Travelers Now Available Knowing Brand Name Equivalents Is Essential to Health and Safety January 19, 2011 (Radnor, PA) —HTH Worldwide, a global health and safety services company, today announced the expansion of its mobile and online brand name medication translation guide for world travelers. Prescrip
Patrick T. Curry, Ph.D. Professional Experience Illinois Institute of Technology, Research Institute Senior Scientist (Section Head, Genetic Toxicology, Microbiology and Molecular Biology Division) Manage a fully GLP compliant genetic toxicology laboratory capable of conducting the complete genetic toxicology test battery (Ames assay, Mouse Lymphoma assay, Structural Chromosome Aberra